Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy

Next Previous
Trial Profile

An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pozelimab (Primary) ; Pozelimab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 12 Dec 2023 Results of psychometric evaluation in patients with Paroxysmal nocturnal hemoglobinuria treated with pozelimab monotherapy or in combination with cemdisiran, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 03 Nov 2023 According to a Regeneron Pharmaceuticals media release, the updated data from this study will be presented at American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.
    • 15 Jun 2023 Results reporting efficacy (LDH) and safety (TEAEs) through weeks 26 (NCT03946748) and long-term efficacy and safety of Pozelimab monotherapy through week 104 (NCT04162470) presented at the 28th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top